Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MN-Gup-GOS
- Development stage
- Unknown
- Lead developer
- Mengniu
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
MN-Gup-GOS is a synbiotic formulation comprising the probiotic strain *Bifidobacterium animalis subsp. lactis* MN-Gup and the prebiotic galactooligosaccharide (GOS). It is primarily investigated for its therapeutic potential in managing type 2 diabetes mellitus (T2DM). The mechanism of action involves the modulation of the gut microbiota, specifically increasing the abundance of beneficial *Bifidobacterium* species, which in turn alters serum bile acid profiles (reducing deoxycholic acid and lithocholic acid) and stimulates the secretion of glucagon-like peptide-1 (GLP-1). Clinical trial results indicate that the synbiotic combination is more effective at reducing fasting blood glucose, hemoglobin A1c, and insulin resistance (HOMA-IR) than the probiotic strain alone, likely due to the synergistic effects of the prebiotic component on microbial metabolism and host endocrine signaling.
- Other names
- Bifidobacterium animalis subsp. lactis MN-Gup + galactooligosaccharideMN-Gup + GOS
02
Targets
Beyond the preview
Go deeper on MN-Gup-GOS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MN-Gup-GOS.